Menu Search
Equities

Vext Science Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
VV5:FRA

Vext Science Inc

Actions
  • Price (EUR)0.166
  • Today's Change0.006 / 3.75%
  • Shares traded24.15k
  • 1 Year change+77.54%
  • Beta0.9078
Data delayed at least 15 minutes, as of Feb 16 2026 07:12 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Vext Science, Inc. is a cannabis operator with vertical operations in Arizona and Ohio. The Company's expertise spans from cultivation through to retail operations in its key markets. The Company owns and operates cultivation facilities, fully built-out manufacturing facilities as well as dispensaries in both Arizona and Ohio. The Company produces a range of branded offerings, including its Vapen, Revibe, Herbal Wellness Center, and Appalachian Pharm lines. The Company manufactures Vapen, one of the THC concentrates, edibles, and distillate cartridge brands in Arizona. It produces CBD products under the Vapen CBD and Hempy Endings brands, manufactured at its Vapen Kentucky facility. Through strategic licensing agreements, it manufactures the Microbar brand in Arizona. The Company extends its services to the cannabis industry by offering management, advisory, cultivation, non-cannabis products, and dispensary services through operating agreements and direct sales to various entities.

  • Revenue in CAD (TTM)65.13m
  • Net income in CAD-22.68m
  • Incorporated2015
  • Employees173.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.